Acoris and c-LEcta to develop synthetic routes for chiral compounds
Acoris Research, a subsidiary of Hikal, and c-LEcta, a German industrial biotech company, are to collaborate on developing synthetic routes for chiral compounds. The partnership combines the expertise of Acoris in process development and small-scale manufacturing with the biocatalysis technologies of c-LEcta.
Acoris Research, a subsidiary of Hikal, and c-LEcta, a German industrial biotech company, are to collaborate on developing synthetic routes for chiral compounds. The partnership combines the expertise of Acoris in process development and small-scale manufacturing with the biocatalysis technologies of c-LEcta.
Acoris, based at the International Biotech Park in Pune, India has a state-of-the-art contract research facility and offers research and manufacturing services, while c-LEcta, based in Leipzig, Germany is an industrial biotech company and holds patent-protected technology for developing industrial enzymes.
Dr R H Rupp, president of Acoris, said: "Enzymatic technologies are a valuable extension of the toolbox and innovative value-creating procedures for client projects. We are glad to announce our partnership with c-LEcta. The combined synergies of our technical collaboration will further enhance our offerings and will be a significant value addition to our clients."
Dr M Struhalla, ceo of c-LEcta, added: "Acoris has state-of-the-art facilities and a pool of world-class scientific talent to work with us on a broad range of enzymes. c-LEcta's proprietary screening technology allows for integration of bioconversion steps early in the route-scouting process."
